Glucaric Acid (D-Glucaric Acid / Saccharic Acid)
1. Identity, Nomenclature, and Chemical Nature
Saccharic acid, also known as glucaric acid, is a dibasic aldaric acid with the chemical formula C₆H₁₀O₈ and the systematic name 2,3,4,5-tetrahydroxyhexanedioic acid. D-Glucaric acid is a six-carbon, straight-chain dicarboxylic acid, sometimes referred to as D-saccharic acid, with the schematic formula COOH–(CHOH)₄–COOH. It is a highly functionalized compound with four chiral carbons.
The salts of D-glucaric acid are referred to as D-glucarates — for example, calcium glucarate, sodium glucarate, magnesium glucarate, and potassium hydrogen glucarate. The calcium salt, known as calcium D-glucarate (CDG), is the primary commercial and supplement form. In supplement form, calcium and glucaric acid are combined to stabilize the glucaric acid; once calcium D-glucarate enters the stomach, it is metabolized to calcium and glucaric acid, with glucaric acid constituting the pharmacologically active component. Calcium D-glucarate contains approximately 9% calcium, which is not a substantial amount and will not replace the need for dietary calcium or a calcium supplement.
Saccharic acid can be prepared by oxidizing both the aldehydic and primary alcohol groups in an aldose, such as glucose, forming the dicarboxylic acid; a suitable reagent for this transformation is boiling 30% nitric acid, resulting in a yield of 50% to 65%. This reaction was first described by German chemist Heinrich Kiliani in 1925. The synthetic preparation of D-glucaric acid dates back even further, to a report by Sohst and Tollens (1888), who carried out the nitric acid oxidation of D-glucose to D-glucaric acid.
In 2004, the U.S. Department of Energy identified glucaric acid as one of the top 12 value-added chemicals from biomass. Beyond its biomedical interest, potential commercial applications for D-glucaric acid include use as a metal sequestering agent, retarding agent for metallic mordants in the dyeing of textiles, and corrosion inhibitor for metals.
2. Natural Sources and Dietary Occurrence
D-Glucaric acid is a natural non-toxic compound produced in small amounts by mammals, including humans. In mammals, D-glucaric acid and D-glucaro-1,4-lactone are end-products of the D-glucuronic acid pathway. In both human and rat liver, as well as skin, glucuronic acid was found to be enzymatically oxidized to glucaric acid; glucaric acid is the sole end product of the glucuronic acid pathway in guinea pigs and primates. A PubMed-indexed study further elucidated the biochemistry: in the presence of iron salts and hydrogen peroxide, D-glucuronic acid was converted into D-glucaric acid — a reaction strongly inhibited by free-radical scavengers and ascribed to the action of the hydroxyl radical.
D-Glucaric acid is a dicarboxylic acid derivatized by oxidation of both the aldehyde and hydroxymethyl group of glucose; it is contained naturally in fruit such as apples and grapefruit and vegetables of Brassicaceae such as broccoli and sprouts. Glucaric acid and glucarate content is high in young seedlings and sprouts but low in their respective seeds.
Quantitative food analysis confirms meaningful variation across produce. A published study (Dwivedi et al., Biochem Med Metab Biol, 1990) found that due to the potential effect of dietary glucarate on net glucuronidation and on other metabolic pathways, glucaric acid levels in various foods were determined; the glucaric acid content varied from a low of 1.12–1.73 mg/100 g for broccoli and potatoes to a high of 4.53 mg/100 g for oranges. A separate study in rats and humans reported that D-glucaric acid content in various fruits and vegetables ranged from about 0.1 g/kg in grapes and lettuce to about 3.5 g/kg in apples and broccoli.
Significant interindividual differences in endogenous glucaric acid levels have been reported in normal healthy populations. It was observed that the urinary excretion of glucaric acid in cancer patients and tumor-bearing rats was significantly lower than in healthy controls; in mice with experimental tumors and in cancer patients, uninvolved liver tissue was found to have a lowered glucaric acid level, and further studies showed that cancerous tissues lack the glucaric acid-synthesizing system. The physiological function of glucaric acid/glucarate remains unclear, although it appears to be an important carbohydrate for cell viability and homeostasis; it is not known whether glucaric acid is an essential nutrient for normal subjects.
3. Commercial Forms and Preparations
In the United States, D-glucaric acid is contained in dietary supplements in the form of calcium D-glucarate. Calcium D-glucarate is legally marketed as a dietary supplement in the United States, reflecting its natural occurrence in small amounts in fruits and vegetables like apples and cruciferous produce. Supplements are most commonly sold as oral capsules or tablets. The compound is also found in combination detoxification formulas alongside other hepatoprotective compounds such as milk thistle, indole-3-carbinol, and B vitamins, though evidence for such combinations is not independently established in the cited literature.
In the GI tract, calcium D-glucarate is metabolized into three compounds, the most active being D-glucaro-1,4-lactone. Biocatalytic production of saccharic acid relies on enzymatic cascades and microbial fermentation to oxidize glucose or related sugars at both the C1 and C6 positions, offering a sustainable alternative to chemical synthesis; these methods leverage biological catalysts for selective oxidation under mild conditions, typically using molecular oxygen as the oxidant.
4. Traditional and Historical Use
Glucaric acid has a history in traditional medicine primarily due to its role in promoting detoxification and supporting overall health. Foods rich in glucaric acid have been valued in various folk remedies for their purported ability to cleanse the body and maintain liver function, though the isolated compound itself was not directly used in ancient remedies; its presence in commonly consumed medicinal plants and fruits underscores its longstanding importance in nutritional and herbal traditions.
Early research in the late 20th century identified its metabolite, D-glucarate, as a possible agent in supporting liver health and facilitating the body's natural elimination of toxins. In traditional herbal medicine, combinations containing glucaric acid-rich ingredients have often been employed to create synergistic detoxifying effects; for instance, herbal blends featuring broccoli, kale, and citrus fruits have been used to support liver health and enhance the body's natural elimination of toxins.
It is important to note that there is no documented tradition of using isolated glucaric acid or its purified salts in pre-modern medicine. The compound was first chemically characterized in the late 19th and early 20th centuries. Its use as a targeted dietary supplement is entirely a product of modern nutritional science, beginning in earnest with laboratory investigations in the 1980s and 1990s, particularly from the work of Walaszek, Webb, Slaga, and their colleagues.
5. Key Constituents and Active Compounds
The pharmacologically relevant species in the glucaric acid supplement system include the parent acid itself and its lactone metabolites. D-glucaro-1,4-lactone is the metabolite that has been shown to inhibit beta-glucuronidase activity, increasing excretion of conjugated xenobiotic compounds and decreasing activity of harmful substances that are most active in their deconjugated state.
In mammals, D-glucaric acid and D-glucaro-1,4-lactone are end-products of the D-glucuronic acid pathway; the enzyme D-glucuronolactone dehydrogenase has been found to be responsible for the oxidation of the lactone of D-glucuronic acid to D-glucaro-1,4;6,3-dilactone; this dilactone hydrolyzes spontaneously in aqueous solution to D-glucaro-1,4-lactone, a potent beta-glucuronidase inhibitor.
Glucarate is normally present in tissues and body fluids and is in equilibrium with D-glucaro-1,4-lactone, a natural inhibitor of beta-glucuronidase activity. Dietary calcium glucarate, a sustained-release form of glucarate, elevates the blood level of D-glucaro-1,4-lactone, which suppresses blood and tissue beta-glucuronidase activity.
6. Mechanisms of Action
6.1 Inhibition of Beta-Glucuronidase and Enhancement of Glucuronidation
Calcium D-glucarate's detoxifying and anticarcinogenic properties are attributed to its ability to increase glucuronidation and excretion of potentially toxic compounds. During Phase II detoxification, chemical carcinogens, steroid hormones, and other lipid-soluble toxins are conjugated with glucuronic acid in the liver (glucuronidation) and excreted through the biliary tract. Beta-glucuronidase is capable of deconjugating these potential toxins, making it possible for them to be reabsorbed rather than excreted.
Most chemical carcinogens and tumor promoters are trapped in the form of a glucuronide, which is then excreted from the body; this process, glucuronidation, is a principal conjugation pathway in vertebrates, and the conjugates of xenobiotics are excreted via the bile and urine. The elimination of potentially damaging chemicals that undergo glucuronidation is not only limited by their rate of conjugation with glucuronic acid, but also by their rate of de-glucuronidation by the ubiquitous enzyme beta-glucuronidase, which hydrolyzes the carcinogen-glucuronide conjugate and thereby frees the carcinogen to inflict damage and produce neoplastic transformations.
Glucaric acid (GA) has been shown to competitively inhibit beta-glucuronidase, which, in the gut lumen, promotes toxicity and generates carcinogenic substances. Glucaric acid inhibits bacterial beta-glucuronidase, thus increasing the excretion of conjugated xenobiotic compounds and decreasing activity of harmful substances; inhibition of beta-glucuronidase ultimately results in potentially decreasing the risk of carcinogenesis.
6.2 Hepatoprotective Mechanisms
A 2023 computational systems biology study published in Nutrients (MDPI) provided an integrative mechanistic account. Computational molecular systems biology analysis of supplementation of calcium and potassium glucarate salts and their metabolite D-glucaric acid (GA) reveals their positive effect on mitigation of liver detoxification via four specific molecular pathways: (1) ROS production, (2) deconjugation, (3) apoptosis of hepatocytes, and (4) beta-glucuronidase synthesis. GA improves liver detoxification by downregulating hepatocyte apoptosis, reducing glucuronide deconjugate levels, reducing ROS production, and inhibiting beta-glucuronidase, which reduces re-absorption of toxins in hepatocytes. Notably, this was an in silico (computational) study, not a human clinical trial.
Previous studies have shown that GA affects the Fenton reaction, a critical step in formation of reactive oxygen species (ROS) such as H₂O₂ and hydroxyl radical, by chelating Fe³⁺.
6.3 Cholesterol and Lipid Modulation
By reducing the beta-glucuronidase viability and activity of intestinal bacteria, salts of D-glucaric acid have been shown to enhance enterohepatic circulation and reduce steady-state levels of cholesterol synthesis, resulting in decreased serum lipid levels. The lipid-lowering effect of calcium D-glucarate may be attributed to improved enterohepatic circulation, resulting in increased excretion of bile acids and a reduction in steady-state levels of cholesterol biosynthesis.
6.4 Steroidogenesis and Hormonal Modulation
D-Glucaric acid is a natural non-toxic compound produced in small amounts by mammals, including humans, and its precursors exert their anticancer action through alterations in steroidogenesis accompanied by changes in the hormonal environment and proliferative status of the target organs. Calcium glucarate also increases estrogen elimination, which may reduce estrogen levels in the body; this explains its use as supportive care among estrogen-sensitive breast cancer patients.
7. Scientific Evidence by Area of Use
7.1 Cancer Chemoprevention
Preclinical (animal) evidence: The bulk of research on glucaric acid's chemopreventive potential derives from animal studies, most prominently by Walaszek and colleagues over several decades. Studies showed that oral supplementation of calcium D-glucarate in rats can inhibit mammary tumor development by over 70% (Walaszek et al., Carcinogenesis, 1986). In studies where D-glucarate was fed to animals, this was always followed by conversion to the D-glucaro-lactone product, and this conversion led to an increase in blood levels of this compound; although carcinogens led to breast cancer in control rats, those fed glucarate did not develop breast cancer.
Work by other investigators, including Walaszek, in 1995 and 1996 showed that calcium D-glucarate and potassium hydrogen D-glucarate were both excellent inhibitors of colon cancer in experimental animal models. In animal studies, calcium glucarate reduced the quantity of benzo[a]pyrene-induced lung lesions with mutated K-ras and p53 genes in the post-initiation phase via DNA adduct removal, mutagenic suppression, and anti-inflammatory activity.
The mechanism of action is related to their abilities to prevent critical carcinogen metabolism and to increase detoxification of carcinogens and tumor promoters. There is now growing evidence for the possible control of different stages of cancer induction by inhibiting beta-glucuronidase with D-glucaric acid derivatives, especially with its salts (D-glucarates). (Hanausek, Walaszek, and Slaga, Integrative Cancer Therapies, 2003.)
In vivo, the D-glucaric acid metabolite, D-glucaro-1,4-lactone, can increase detoxification of carcinogens and inhibit chemically induced carcinogenesis in animals, in part by inhibiting beta-glucuronidase.
Human/clinical evidence: Although lab studies suggest anticancer effects, calcium glucarate has not been shown to treat or prevent cancer in humans. No clinical trials have tested whether calcium glucarate has these effects in humans. The sole human-level data cited in the literature comes from a small Phase I study. The calcium salt of the acid demonstrated anti-cancer activity in patients with breast cancer in a Phase I clinical trial, and in preclinical models of liver, lung, colon, and skin cancers. This is cited by the U.S. National Center for Advancing Translational Sciences (NCATS) Inxight Drugs database as a Phase I result, indicating safety and preliminary signal evaluation — not proof of efficacy. Only one small study in humans suggests that calcium glucarate supplementation might reduce cancer risk for some individuals; more well-designed studies are needed to confirm such effects. (Memorial Sloan Kettering Cancer Center.)
Overall, there is almost zero clinical evidence to support its purported benefits in humans. Evidence remains essentially preclinical.
7.2 Estrogen Metabolism and Hormone-Dependent Conditions
Calcium D-glucarate inhibits beta-glucuronidase, an enzyme that reverses estrogen and toxin conjugation in the gut, thereby supporting estrogen elimination; at 1500–3000 mg daily, it may help maintain healthy estrogen levels by preventing reabsorption of conjugated estrogens. Clinical evidence in humans is preliminary, but the mechanism is well-characterized biochemically.
In rats, dietary D-glucaric acids reduced circulating levels of estrogens, possibly as a result of increased excretion as glucuronides; however, direct inhibition of rat liver or blood beta-glucuronidase activity was not found in all models.
Rigorous human clinical trials specifically for calcium D-glucarate in estrogen metabolism or cancer prevention are lacking; the supplement's popularity is largely based on the well-characterized biochemistry, animal data, and logical extrapolation to human estrogen metabolism rather than direct human RCT evidence.
7.3 Cholesterol and Cardiovascular Lipids
Purified diets containing calcium D-glucarate or potassium hydrogen D-glucarate markedly lowered serum levels of cholesterol in female Sprague-Dawley rats; the D-glucarates reduced total serum cholesterol in rats by up to 14% (P<0.05) and lowered LDL-cholesterol by up to 35% (P<0.05), but had no effect on HDL cholesterol. (Walaszek et al., Nutrition Research, 1996.)
Some preliminary human data exists: Calcium D-glucarate has been shown to significantly reduce total serum cholesterol in rats by as much as 12–15% and LDL-cholesterol by 30–35%; preliminary results in humans show calcium D-glucarate reduced total serum cholesterol up to 12%, LDL-cholesterol up to 28%, and triglycerides up to 43%. These human figures originate from unpublished or conference proceedings data (e.g., Walaszek et al., FASEB, 1991) and have not been confirmed in large, controlled clinical trials.
Animal studies revealed that calcium D-glucarate lowers total and LDL cholesterol in the blood. The evidence for lipid-lowering in humans must be considered preliminary and unconfirmed by peer-reviewed RCT data.
7.4 Liver Detoxification Support
Glucaric acid plays a hepatoprotective role by lowering glucuronide deconjugate levels, which are implicated in promoting liver toxicity and subsequent liver damage; this can be attributed to GA's inhibition of beta-glucuronidase, which catalyzes the deconjugation of endotoxin-glucuronic acid complexes.
No randomised controlled trials have evaluated calcium D-glucarate specifically for non-alcoholic fatty liver disease (NAFLD) treatment; the compound is not authorised by the MHRA or recommended in NICE guidance for any liver-related indication. While this biochemical mechanism is well characterised in laboratory studies, the clinical significance of inhibiting beta-glucuronidase in humans remains uncertain and unproven.
7.5 Lung Cancer Chemoprevention (Animal Data Only)
Walaszek, Hanausek, Narog, Raich, and Slaga published data in Chest (2004) on mechanisms of lung cancer chemoprevention by D-glucarate. Animal studies showed calcium glucarate reduced the quantity of benzo[a]pyrene-induced lung lesions with mutated K-ras and p53 genes in the post-initiation phase via DNA adduct removal, mutagenic suppression, and anti-inflammatory activity. No human trials in this context have been reported.
7.6 Summary of Evidence Strength
- Mechanism of beta-glucuronidase inhibition: Well-established biochemically in vitro and in animal models; confirmed in rats in vivo.
- Anticancer chemoprevention: Strong preclinical (animal) evidence; single Phase I human trial; no efficacy RCTs in humans.
- Estrogen/hormone metabolism: Mechanistically plausible; supported by animal data; human RCT evidence absent.
- Cholesterol/lipid reduction: Robust animal evidence; limited, unconfirmed human preliminary data only.
- Liver protection: Supported by in silico and animal data; no human RCTs.
8. Body Systems and Health Areas of Association
- Hepatic (liver) system: Phase II detoxification (glucuronidation pathway), hepatoprotection, bile acid metabolism.
- Gastrointestinal system: Modulation of intestinal bacterial beta-glucuronidase activity; enterohepatic circulation of bile acids and steroids.
- Endocrine/hormonal system: Estrogen metabolism and excretion; steroidogenesis modulation; potential relevance to estrogen-dominant conditions.
- Oncology/cancer prevention: Breast, colon, lung, liver, and skin cancer chemoprevention — extensively studied in animals, with very limited human evidence.
- Cardiovascular system: Cholesterol and LDL reduction — animal data, preliminary human data.
- Detoxification: Enhanced excretion of carcinogens, environmental toxins, and xenobiotics via glucuronidation support.
9. Dosage Forms and Reported Dosages
There is no established Recommended Dietary Allowance (RDA) for glucaric acid.
In human trials for cancer prevention, dosages ranged from 1.5 to 9 grams per day, although the generally recommended oral dosage is 1.5 to 3 grams daily. Because of the lack of research, the optimal dosage and timing are still unknown.
At 1500–3000 mg daily, calcium D-glucarate may help maintain healthy estrogen levels by preventing reabsorption of conjugated estrogens, according to the proposed biochemical mechanism.
For those taking supplements, typical doses of calcium D-glucarate range from 200 to 1,200 milligrams per day.
In the key animal experiment by Dwivedi et al. (1990): a single dose of calcium glucarate (4.5 mmole/kg body weight) inhibited beta-glucuronidase activity in serum and liver, lung, and intestinal microsomes by 57%, 44%, 37%, and 39%, respectively; a chronic administration of calcium glucarate (4% in diet) also decreased beta-glucuronidase activity in intestinal and liver microsomes.
The computational study by Meyers et al. (Nutrients, 2023) modeled effects of: GA supplementation levels of 0, 26 mg, and 52 mg, examining effects on the deconjugation pathway.
10. Safety Considerations and Drug Interactions
10.1 General Safety Profile
Glucaric acid and glucarates are generally non-toxic, and no adverse effects have been observed from prolonged feeding of potassium hydrogen glucarate to rats or calcium glucarate to rats and mice. Calcium D-glucarate appears generally well tolerated at common doses, though long-term safety data and drug interaction profiles are limited.
The FDA has not reviewed calcium D-glucarate for safety and effectiveness.
10.2 Drug Interactions via Glucuronidation Pathway
Calcium D-glucarate may theoretically affect the metabolism of certain medications that undergo glucuronidation; however, these interactions are largely theoretical and not well documented in human studies.
Calcium D-glucarate might increase how quickly some medications are broken down by the liver; taking calcium D-glucarate along with medications changed by the liver might decrease the effectiveness of these medications. Some of these medications changed by the liver include acetaminophen (Tylenol), atorvastatin (Lipitor), diazepam (Valium), digoxin, entacapone (Comtan), estrogen, irinotecan (Camptosar), lamotrigine (Lamictal), lorazepam (Ativan), lovastatin (Mevacor), and others. This list is based on pharmacological reasoning (all are substrates of glucuronidation enzymes), not confirmed interaction studies.
Alcohol might increase how fast the body gets rid of calcium D-glucarate, thereby potentially decreasing the effectiveness of calcium D-glucarate.
If a medication is processed through Phase II liver detoxification (glucuronidation), it could potentially be cleared faster, which may make it less effective for some people; it is best to avoid calcium D-glucarate during pregnancy or breastfeeding because there is insufficient safety and dosing research in these populations.
10.3 Gastrointestinal Effects
Potential mild side effects include gas or digestive discomfort. These represent the most commonly reported adverse effects and are considered minor.
10.4 Context for Supplement Use
There is no proof that taking calcium D-glucarate treats or prevents cancer. The compound remains an investigational nutraceutical with well-characterized biochemical mechanisms but an insufficient body of controlled human evidence to support clinical recommendations for any specific indication. No clinical evidence supports the use of calcium glucarate for any of the conditions listed in the literature; the existing animal and cell-based research should guide further investigational efforts.
References
Go back